Glioblastoma Imaging Using a Strong Iron-like Bloodpool Contrast Medium?

Trial Title: Glioblastoma Imaging Using a Strong Iron-like Bloodpool Contrast Medium?

NCT ID: NCT05656300

Condition: Glioblastoma

Conditions: Official terms:
Glioblastoma

Study type: Observational [Patient Registry]

Overall status: Not yet recruiting

Study design:

Time perspective: Prospective

Intervention:

Intervention type: Diagnostic Test
Intervention name: MRI scan using USPIO particles
Description: Diagnostic imaging

Summary: Rationale: Visualization of tumor spread is of crucial importance when treating patients suffering from glioblastoma (GBM) as the success of tumor resection depends strongly on the extent of tumor infiltration. Current MRI protocols, however, cannot visualize the extent the tumor infiltration. The use of non-toxic, non-dangerous ultrasmall superparamagnetic biodegradable iron oxide (USPIO) particles as a very strong blood pool contrast agent could help visualizing this invisible infiltration Objective: To what extent, do GBMs infiltrate healthy brain tissue and can we use ultrasmall superparamagnetic iron oxide particles to visualize co-opting infiltrating tumor cells in an attempt to predict regions of tumor recurrence? Study design: This study concerns a single arm prospective observational study. Study population: Patients diagnosed with suspected glioblastoma. Intervention (if applicable): USPIO neuroimaging Main study parameters/endpoints: The main parameter of this study concerns the feasibility of using of USPIO particles in healthy controls (n=6) and glioblastoma patients (n=15). Nature and extent of the burden and risks associated with participation, benefit and group relatedness: During this study patients will be intravenously injected with low doses of USPIOs. Risks involved with this procedure include: bruising of the skin after venapunction and allergic reaction to USPIO particles. The application of USPIO neuroimaging can improve diagnosis of patients with suspected glioblastoma, provide more information on the pathophysiology of growth of glioblastoma lesiosn, the role of neuro-inflammation in these lesions and maybe predict regions of tumor recurrence after treatment.

Criteria for eligibility:

Study pop:
Clinicians will recruit men and women diagnosed with a suspected glioblastoma who are scheduled to undergo neurosurgical resection and/or chemoradiation therapy as treatment.

Sampling method: Non-Probability Sample
Criteria:
Inclusion Criteria: - Aged between 18 and 75 years - Diagnosed with suspected glioblastoma - Eligible for neurosurgical resection and/or chemoradiation therapy. Exclusion Criteria: - Younger than 18 years old - Patients unfit for surgery or lesions unsuitable for neurosurgical treatment

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Start date: April 1, 2023

Completion date: April 1, 2025

Lead sponsor:
Agency: Radboud University Medical Center
Agency class: Other

Collaborator:
Agency: ZonMw: The Netherlands Organisation for Health Research and Development
Agency class: Other

Source: Radboud University Medical Center

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT05656300